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Abstract Although oligodendroglial neoplasms are tra-
ditionally considered purely glial, increasing evidence
suggests that they are capable of neuronal or neurocytic
differentiation. Nevertheless, ganglioglioma-like foci
(GGLF) have not been previously described. Herein, we
report seven examples where the primary differential
diagnosis was a ganglioglioma with an oligodendroglial
component. These ﬁve male and two female patients ran-
ged in age from 29 to 63 (median 44) years at initial
presentation and neuroimaging features were those of dif-
fuse gliomas in general. At presentation, the glial
component was oligodendroglioma in six and oligoastro-
cytoma in one; one was low-grade and six were anaplastic.
A sharp demarcation from adjacent GGLF was common,
although some intermingling was always present. The
GGLF included enlarged dysmorphic and occasionally
binucleate ganglion cells, Nissl substance, expression of
neuronal antigens, GFAP-positive astrocytic elements, and
low Ki-67 labeling indices. In contrast to classic ganglio-
glioma, however, cases lacked eosinophilic granular bodies
and CD34-positive tumor cells. Scattered bizarre astrocytes
were also common and one case had focal neurocytic dif-
ferentiation. By FISH analysis, ﬁve cases showed 1p/19q
codeletion. In the four cases with deletions and ample
dysmorphic ganglion cells for analysis, the deletions were
found in both components. At last follow-up, two patients
suffered recurrences, one developed radiation necrosis
mimicking recurrence, and one died of disease 7.5 years
after initial surgery. We conclude that GGLF represents yet
another form of neuronal differentiation in oligodendrog-
lial neoplasms. Recognition of this pattern will prevent a
misdiagnosis of ganglioglioma with its potential for under-
treatment.
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Introduction
Oligodendroglioma was originally deﬁned by Bailey and
Bucy [3] in 1929 as a glioma subtype with cells that
morphologically resembled normal oligodendrocytes. To a
great extent, that deﬁnition still pertains today [30].
Nonetheless, there has been great controversy over the
minimal criteria required for this diagnosis. Since the
A. Perry (&)  S. S. Burton
Division of Neuropathology, Washington University School
of Medicine, 660 Euclid Avenue, Box 8118, St. Louis,
MO 63110-1093, USA
e-mail: aperry@wustl.edu
G. N. Fuller
University of Texas MD Anderson Cancer Center,
Houston, TX, USA
C. A. Robinson
University of Saskatchewan, Saskatoon, SK, Canada
C. A. Palmer
University of Alabama at Birmingham, Birmingham, AL, USA
L. Resch
University of Alberta, Edmonton, AB, Canada
E. H. Bigio
Northwestern University Medical School, Chicago, IL, USA
M. Gujrati
University of Illinois College of Medicine at Peoria,
Peoria, IL, USA
M. K. Rosenblum
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
123
Acta Neuropathol (2010) 120:237–252
DOI 10.1007/s00401-010-0695-9initial discovery that this tumor type is associated with a
useful genetic signature predicting favorable prognosis and
enhanced therapeutic sensitivity [1, 9, 14, 31, 33], there has
been renewed interest in fully characterizing the morpho-
logic and biologic spectra of oligodendroglial neoplasms.
One surprising ﬁnding from this pursuit has been that
despite considering oligodendroglioma a purely glial neo-
plasm, they can show neuronal features at multiple levels,
including immunohistochemically, ultrastructurally, in
vitro, and on expression proﬁling studies [11, 13, 20, 22–
25, 27, 28, 36, 38–40]. In most of these cases, the neuronal
phenotype is not evident by routine histology alone.
Nonetheless, we and others have reported rare examples
with overt neurocytic differentiation, associated with
slightly smaller darker nuclei, as well as neuropil and
rosette formation [20, 22, 28, 36]. When this neurocytic
differentiation is extensive, the distinction from extraven-
tricular neurocytoma can be extremely difﬁcult. In such
cases, however, the presence of chromosome 1p and 19q
codeletion strongly favors the interpretation of oligoden-
droglioma with neurocytic features. The behavior of these
tumors appears to be essentially that of grade matched
oligodendrogliomas without neurocytic features based on
the limited number of cases reported to date. In the current
study, a somewhat analogous situation is described, where
the neuronal differentiation, instead, bears striking simi-
larities to ganglioglioma, a signiﬁcant diagnostic pitfall,
since this glioneuronal neoplasm is much more indolent
and has completely different therapeutic implications. To
our knowledge, this morphologic pattern has not been
previously reported.
Materials and methods
The cases reported in this series were encountered by the
authors at their home institutions and on the consult service
at Washington University, St. Louis, between 2001 and
2010. They were all sent to one of the authors (AP)
for second opinion regarding the diagnosis or genetic
conﬁrmation of the oligodendroglioma component.
Immunohistochemical studies were performed as part of
the diagnostic workup using standard antibodies and
techniques, either by the referring pathologist or as part of
the consult workup.
Dual-color FISH was performed as previously published
with slight modiﬁcation of the interpretation criteria [12].
Deparafﬁnization of the sections was carried out using two
10-min immersions in Citrisolv, followed by three 3-min
immersions in isopropanol. The slides were next rinsed in
running water for 5 min, followed by distilled water for
3 min. Target retrieval was achieved by immersing the
slides in citrate buffer (pH 6.0) within a plastic Coplin jar
which was steamed a total of 20 min, then slowly cooled to
room temperature. The slides were then rinsed in running
water for 5 min, followed by distilled water for 3 min.
Sections were subjected to 0.4% pepsin (P-7012, Sigma-
Aldrich, St. Louis, MO) digestion for 15 min (37C) and
then were placed in 29 SSC on a rotator for 5 min. Slides
were then air-dried. Paired probes for 1p32/1q42 and
19p13/19q13 were diluted from stock at 1:25 using Den-
Hyb buffer (Insitus Biotechnologies; Albuquerque, NM),
applied to each slide and co-denatured with the target DNA
at 90C for 13 min. The slides were incubated overnight at
37C in a humidiﬁed oven and subsequently washed for
5 min each with 50% formamide/19 SSC and two washes
in 29 SSC. Depending on the surface area of the section to
be covered, 10–20 lL of DAPI in Fluorguard (Insitus) was
applied to each slide, which was then coverslipped. Green
and red ﬂuorescent signals were enumerated under an
Olympus BX60 ﬂuorescence microscope with appropriate
ﬁlters (Olympus; Melville, NY). For each case, green and
red signals were enumerated in 100–200 consecutive non-
overlapping nuclei in each of the two basic morphologic
patterns: oligodendroglioma and ganglioglioma-like foci
(GGLF). In cases where the two phenotypes were inter-
mixed, larger dysmorphic appearing nuclei were counted
separately from the smaller oligodendroglioma-like nuclei.
In cases where 100 large dysmorphic nuclei were not found
or for which there were no adequate signals for reliable
interpretation, they were considered non-informative for
this portion of the tumor. Similarly, at least 90% of nuclei
in any given region had to have interpretable signals for a
case to be considered informative. An interpretation of
deletion for either 1p or 19q was made when [25% of
tumor nuclei harbored twice as many reference probes as
test probe signals (e.g., patterns of 2:1, 4:2, 6:3, etc.). This
criterion has been used in our clinical FISH lab for several
years and is based on similar analyses in non-neoplastic
CNS nuclei, using the median percentages for the 2:1
pattern plus three standard deviations. Cutoffs of polyso-
mies (chromosomal gains) were set at 10%. FISH images
were captured using a black and white, high-resolution
COHU CCD camera, Z-stack motor and CytoVision
TM
basic workstation (Applied Imaging, Santa Clara, CA),
with sequential DAPI (1 level), FITC (5 levels), and rho-
damine (5 levels) ﬁlter settings. The resulting images were
reconstituted with blue, green, and red pseudocolors using
CytoVision
TM software.
Results
Clinical, radiographic, pathological, and genetic features
are summarized in Tables 1, 2 and 3, with more detailed
descriptions below.
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123Case 1
This 44-year-old man presented with a 3-day history of
progressive headaches. A head CT revealed a contrast
enhancing right frontal mass with a posterior cystic com-
ponent and associated vasogenic edema. Subsequent MRI
similarly revealed a 6 9 3.9 9 5.3 cm heterogeneous,
partially enhancing, partially cystic, right frontal mass with
moderate cerebral edema, midline shift, and extension into
the corpus callosum (Fig. 1a–c). A resection of the
enhancing component was performed, followed by adju-
vant radiation therapy (6,000 cGy over 30 fractions over
6 weeks). The patient remained stable until 1.3 years post-
operatively, when he suffered worsening headaches once
again. Neuroimaging revealed a focus of ring enhancement
in the right frontal lobe, with several smaller nodular foci
of contrast enhancement nearby. Radiologically, recurrent
tumor was favored and the patient was therefore treated
with temozolomide chemotherapy. Three months later, this
focus appeared larger (Fig. 1d), prompting a second
resection, which revealed radiation necrosis without any
viable tumor. Over the next 6 months, the cavity margins
developed further foci of contrast enhancement prompting
a third surgery, which again showed only radiation
Table 1 Clinical features in cases of oligodendroglioma with ganglioglioma-like maturation
Case Age/sex Site Imaging features Therapy Clinical follow-up
1 44 M RFL Het E, ME, cystic STR, RT, TMZ A 2.1 yrs, rad nec 9 2
2 58 M LTL Non-E, ME STR, RT, TMZ
a D 7.5 yrs, rec 2.8, 6.1 yrs
3 40 M RFPL Het E, ME, Ca
2?, CC STR, TMZ A 4.9 yrs
4 29 F LFL Het E, ME, cystic STR, TMZ A 3.5 yrs, rec 2.2 yrs
5 55 M RFL Het E, ME, cystic, CC STR, RT A 8 months
6 63 F LFL Min E, ME, CC STR, RT, TMZ A 1 month
7 42 M RFL Het E, ME, cystic STR, RT, TMZ Recently diagnosed
M Male, F female, R right, L left, FL frontal lobe, TL temporal lobe, FPL fronto-parietal lobe, Het E heterogeneously enhancing, Non-E non-
enhancing, Min E minimally enhancing, ME mass effects, Ca
2? calciﬁed, CC corpus callosum involvement, STR subtotal resection, RT radiation
therapy, TMZ temozolomide chemotherapy, A alive, D dead, rad nec radiation necrosis, rec recurrence at, yrs years
a Accutane and marimastat therapy as well
Table 2 Pathologic features in cases of oligodendroglioma with ganglioglioma-like maturation
Case O (or OA)–GG
interface
WHO
grade
Astro Neurocytic Immunoproﬁle
1 Sharp III Yes No GFAP (O GG), SYN (O GG), NFP (GG), Neu-N-, CD34-, Ki-67 = 44% (O),\1% (GG)
2 Sharp III Yes No GFAP (O GG), SYN (GG), Neu-N (GG), CD34-, Ki-67 = 4% (O),\1% (GG)
3 Sharp and
diffuse
III Yes No GFAP (O GG), SYN (O GG), Neu-N-, CD34-, Ki-67 = 15% (O),\1% (GG)
4 Diffuse III No No GFAP (O GG), SYN (O GG), NFP (GG), Neu-N (GG), CD34-, Ki67 = 12% (GG),
\1% (GG)
5 Sharp II Yes No GFAP (O GG), SYN (GG), Neu-N-, CD34-, Ki-67 = 8% (O),\1% (GG)
6 Diffuse III Yes Yes GFAP (O GG), SYN (GG), NFP (GG), CG (GG), Neu-N (GG), CD34-, Ki-67 = 10% (O),
\1% (GG)
7 Sharp and
diffuse
III Yes No GFAP (OA GG), SYN (GG), NFP-, CG (GG), Neu-N-, CD34-, Ki-67 = 12% (O),
\1% (GG)
O Oligodendroglioma component, OA oligoastrocytoma component, GG ganglioglioma-like foci, WHO World Health Organization grade,
Neurocytic neurocytic component, GFAP glial ﬁbrillary acidic protein, SYN synaptophysin, NFP neuroﬁlament protein
Table 3 Genetic features in cases of oligodendroglioma with gan-
glioglioma-like maturation
Case Oligo component GGLF
1 1p-deleted, 19q-deleted 1p-deleted, 19q-deleted
2 1p-deleted, 19q-deleted Non-informative
3 19q-deleted, 1p/19q LOH
a 19q-deleted
4 1p-deleted, 19q-deleted Non-informative
5 1p-deleted, 19-normal 1p-deleted, 19-normal
6 1p-deleted, 19q-deleted 1p-deleted, 19q-deleted
7 Polysomies of 1 and 19 Polysomies of 1 and 19
a Genetic status was determined by FISH in all cases, although loss of
heterozygosity studies were also performed in case 3 and this veriﬁed
the1plossforthiscase,sincechromosome1statuswasnon-informative
byFISH. The LOH studieswerenot performed speciﬁcally inGGLF, so
the status of 1p within dysmorphic neurons was not known in this case
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123necrosis. The patient was last seen 2.1 years after the initial
surgery and is doing well.
The pathology specimen from the ﬁrst surgery revealed a
neoplasm containing two distinct morphologic appearances
with relatively sharp demarcation between them (Fig. 2a),
butsomeintermingling.Oneportionofthetumorhadclassic
features of anaplastic oligodendroglioma, including an
inﬁltrative growth pattern, uniformly rounded nuclei with
delicate chromatin, clear perinuclear haloes, scattered
minigemistocytes, nests of slightly larger more epithelioid
cells, a rich branching capillary network, increased mitotic
activity(upto10 per10 highpoweredﬁelds), microvascular
proliferation, and foci of non-palisading tumor necrosis
(Fig. 2b, d, f). The second component resembled ganglio-
glioma and included large dysmorphic cells arranged in
nests and sweeping fascicles, subsets of which had dis-
cernable Nissl substance and/or showed binucleation
(Fig. 2c, e, g). Additionally, there was focal perivascular
lymphocytic cufﬁng and scattered spindled cells with
eosinophilic cytoplasm resembling astrocytes. However, no
eosinophilic granular bodies (EGBs) were detected. Mitotic
ﬁgures were hard to ﬁnd and there was no necrosis or
microvascular proliferation. On immunohistochemical
studies, GFAP highlighted glioﬁbrillary oligodendrocytes
and minigemistocytes within the oligodendroglioma com-
ponent and astrocytic cells within the GGLF (Fig. 3a, b).
Synaptophysin expression was similarly seen in both com-
ponents, but yielded a cytoplasmic dot-like pattern in the
oligodendroglioma (Fig. 3c) and cytoplasmic and/or mem-
branestaininginthedysmorphicganglioncellsoftheGGLF
(Fig. 3d). Cytoplasmic neuroﬁlament expression was seen
in only a minor subset of oligodendroglioma cells, although
entrapped axons were highlighted, consistent with an inﬁl-
trative growth pattern (Fig. 3e). Strong neuroﬁlament
positivity was seen in ganglion cells and their processes
within the GGLF (Fig. 3f). A CD34 stain highlighted
endothelial cells, but all tumor cells were immunonegative.
The Ki-67 labeling index was markedly elevated in the
oligodendroglial portions, reaching up to 44% (Fig. 3g). In
contrast, only rare Ki-67 positive nuclei were seen in the
GGLF, some of which likely represented perivascular
inﬂammatory cells (Fig. 3h). FISH analysis revealed 1p and
19q codeletion in both components (Fig. 4).
Case 2
This 58-year-old man presented with progressive dyscal-
culia and short-term memory loss. MRI revealed a poorly
Fig. 1 Pre-operative MR
images from patient 1 showing a
partially enhancing ill-deﬁned
right frontal lobe mass with
extension into the corpus
callosum on sagittal post-
contrast T1-weighted (a), axial
T2-weighted (b), and axial post-
contrast T1-weighted (c)
images. A rim enhancing mass
detected over 1 year post-
operatively (d) prompted
re-resection for suspected
recurrence, but the specimen
showed only radiation necrosis
on pathological examination
240 Acta Neuropathol (2010) 120:237–252
123Fig. 2 The histology from case
1 showed relative demarcation
of areas resembling
oligodendroglioma (a; left) and
areas resembling ganglioglioma
(a; right). Higher magniﬁcation
images are shown of the
oligodendroglioma (b, d, f) and
GGLF (c, e, g). Classical
oligodendroglial features
included uniform round nuclei,
clear haloes,
microcalciﬁcations, and
chicken-wire like capillaries
(b). Anaplastic features
included necrosis and
microvascular proliferation (d),
as well as increased mitotic
activity (f, arrow).
Ganglioglioma-like features
included large dysmorphic
appearing cells with abundant
eosinophilic to amphophilic
cytoplasm, occasional Nissl
substance (e, g), scattered
perivascular lymphocytes (e),
and a paucity of mitotic activity.
Occasional binucleate forms
were also seen (g, arrow)
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123demarcated, non-enhancing left temporo-parietal mass felt
radiologically to be consistent with a diffuse glioma. A
stereotactic biopsy was performed, but was non-diagnostic.
This was followed by a subtotal resection utilizing cavi-
tronic ultrasonic aspiration (CUSA), followed by
intraoperative Gliadel
 wafer implantation within the sur-
gical cavity. Unfortunately, the resulting specimen was
poorly preserved and only a descriptive diagnosis of
‘‘diffuse glioma’’ was possible at that time (slides from
outside hospital unavailable for further review). No deﬁnite
neuronal component was evident by report, although this
may have been difﬁcult to discern due to poor specimen
quality. The patient was subsequently treated with standard
fractionated radiotherapy over 4 months and the tumor
remained stable for the next 4.4 years, at which time
neuroimaging revealed a new focus of contrast enhance-
ment consistent with recurrence. The enhancing component
was resected. The patient was subsequently treated with a
temozolomide and marimastat chemotherapy regimen with
good response and stable disease for the next 3 years. At
this time, temozolomide therapy was reinstituted due to
another new focus of contrast enhancement. However, the
tumor continued to progress and the patient expired
7.5 years from initial presentation.
The pathology of the recurrent tumor resembled ana-
plasticoligodendroglioma,WHOgradeIIIinthemajorityof
slides (Fig. 5a). Features included diffuse inﬁltration,
uniform round nuclei with small nucleoli and clear
perinuclear haloes, branching ‘‘chicken-wire’’ capillaries,
scattered minigemistocytes, increased mitotic activity, and
Fig. 3 Immunohistochemical
studies in case 1 with the
oligodendroglioma component
on the left and the
ganglioglioma-like component
on the right. GFAP highlighted
glioﬁbrillary oligodendrocytes
(a) and astrocytic cells (b).
Synaptophysin yielded a
cytoplasmic dot-like pattern in
the oligodendroglioma (c) and
cytoplasmic/membrane pattern
staining of dysmorphic ganglion
cells (d). Only rare
oligodendroglial cells stained
with neuroﬁlament protein,
although entrapped axons in this
component were consistent with
an inﬁltrative growth pattern
(e). Many of the dysmorphic
ganglion cells and their
processes expressed
neuroﬁlament (f). The Ki-67
labeling index reached up to
44% in the oligodendroglioma
component (g), but was\1% in
the ganglioglioma-like foci (h)
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123microvascular proliferation. No necrosis was seen. Focally,
GGLFwere identiﬁedandtheyappearedmostlydemarcated
from the adjacent oligodendroglioma pattern (Fig. 5b). This
portion included a microcystic background and scattered
markedly enlarged, mildly dysmorphic ganglion cells with
occasionalbinucleate ormultinucleate forms (Fig. 5c).Rare
bizarre astrocytes were also noted (Fig. 5d). No EGBs were
found. Immunohistochemical studies revealed GFAP
positivity in a subset of the oligodendroglioma cells,
morphologically consistent with minigemistocytes and
glioﬁbrillary oligodendrocytes. The rare bizarre astrocytes
were also positive. Dysmorphic ganglion cells were immu-
noreactive for synaptophysin and Neu-N, while oligo-
dendroglioma cells were negative. CD34 was negative in
tumor cells, but labeled endothelial cells appropriately.
The Ki-67 labeling index was estimated at 4% within the
Fig. 4 FISH studies in the
oligodendroglioma component
revealed 1p and 19q codeletion
with most nuclei being near
diploid (not shown). In the
ganglioglioma-like foci, there
was similarly a codeletion
pattern with a mixture of near-
diploid (1 test and 2 reference
probe signals/cell; arrows) and
near-tetraploid (arrowheads)
populations, the latter
containing up to four red 1q and
two green 1p signals (a) and up
to four green 19p and two red
19q signals (b) (some cells have
fewer signals because they are
either out of the plane of focus
or truncated during parafﬁn
sectioning)
Fig. 5 The histological features
in case 2 were predominantly
those of an anaplastic
oligodendroglioma, including
round regular nuclei, small
nucleoli, clear perinuclear
haloes, and a rich branching
capillary network (a). The
oligodendroglioma (b; left) was
sharply demarcated from
adjacent small GGLF (b; right).
The latter contained a neuropil-
rich microcystic background,
with large mildly dysmorphic
ganglion cells, including
binucleate forms (c; arrow).
Rare, bizarre multinucleate
astrocytes were also found (d)
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123oligodendrogliomacomponentand\1%intheGGLF.FISH
analysis revealed 1p and 19q codeletion in the oligoden-
droglioma. There were insufﬁcient numbers of dysmorphic
ganglion cells for reliable counts in the GGLF.
Case 3
This 40-year-old man developed daily headaches and was
referred toanophthalmologistwhenthesewerecomplicated
byvisualblurring.Fundoscopicexamrevealedpapilledema,
prompting imaging studies. Head CT and MRI scans dem-
onstrateda5-cmpartiallycalciﬁed,partiallyenhancingright
frontoparietal mass with extension into the splenium of the
corpus callosum. There was associated cerebral edema and
mass effect with compression of the right lateral ventricle.
On the day of the MRI, the patient developed left sided
weakness and had a seizure. The patient subsequently
underwent a craniotomy with resection of the contrast
enhancing component and a portion of the non-enhancing
component. Adjuvant therapy included 12 cycles of tem-
ozolomide chemotherapy, but this had to be discontinued
after the 12th cycle due to severe rash. The last MRI scan
performed 4.9 years after initial presentation showed stable
disease with residual non-enhancing tumor and otherwise,
the patient is doing well.
The pathologic ﬁndings in case 3 were nearly identical to
those of case 2, except that there was a greater degree of
intermingling between the two elements and the zones of
infarct-like necrosis within the oligodendroglial component
were larger. Synaptophysin staining revealed strong cyto-
plasmic and Golgipatternpositivity in dysmorphic ganglion
cells, while only rare oligodendroglial cells showed cyto-
plasmic reactivity. There was extensive GFAP positivity
with most positive cells showing morphologic features of
glioﬁbrillary oligodendrocytes. However, irregular cells
with elongate processes were also seen, suggesting a minor
astrocytic component. Both components were Neu-N neg-
ative. The CD34 stain highlighted endothelial cells only;
tumorcellswerenegative.TheKi-67labelingindexwaslow
to moderate, focally reaching a maximal staining of 15% in
the oligodendroglial component; it was \1% in GGLF.
FISH analysis revealed chromosome 19q deletion in both
components, while chromosome 1 studies were non-infor-
mative due to weak signals. Nevertheless, loss of
heterozygosity studies were also performed on this tissue at
the Memorial Sloan Kettering Cancer Center and allelic
losses of both 1p and 19q were detected. Therefore, this
tumor was interpreted as being codeleted.
Case 4
This 29-year-old woman was previously healthy until she
awoke with a severe left frontal headache associated with
nausea and vomiting. A few days later, she had a similar
episode, prompting medical attention. A head MRI scan
demonstrated a large, partially enhancing, left frontal
lesion with some mass effect including mild left-to-right
shift and compression of the ipsilateral ventricle. There was
some high attenuation on pre-gadolinium images. It also
had some hypodense and cystic areas. It did not appear to
cross the corpus callosum. A left frontal craniotomy with
intraoperative motor and speech mapping was performed
and the entire enhancing component was resected. A
decision was made not to treat the neoplasm with radiation
or chemotherapy, but to follow with frequent MRI scans.
Over the next 2 years, the patient remained asymptom-
atic and MRI scans were stable. Eventually however, they
revealed gradually increasing areas of FLAIR abnormality
and a small area of new enhancement situated near the
anterior pole of the surgical cavity. The corpus callosum
was thickened and the neoplasm had now extended into the
right frontal lobe. Therefore, a second resection was per-
formed roughly 2.2 years after her initial presentation. The
patient was treated post-operatively with 12 cycles of
temozolomide chemotherapy. At her last follow-up visit
3.5 years from the ﬁrst surgery, she was doing well with
stable disease on imaging studies.
The ﬁrst pathology specimen revealed a neoplasm that
was mostly consistent with oligodendroglioma, WHO grade
II, but focally showed small foci of enlarged epithelioid
cells with increased cytoplasm, nucleolar prominence, and
increased mitotic activity of up to 6 mitoses per 10 high
powered ﬁelds, warranting a designation of focal anaplasia,
WHO grade III. Small clusters of minigemistocytes were
seen in a few areas. In addition there were multiple small
GGLF that were mostly intermingled with the rest of the
tumor. These foci included large, dysmorphic, occasionally
binucleate ganglion cells embedded within collections of
loose to microcystic, delicate ﬁbrillary matrix, consistent
with tumor-associated neuropil. A small subset of these
dysmorphic cells contained discernable Nissl substance. No
EGBs or bizarre astrocytes were seen in either component.
The recurrent tumor showed similar features, but had only
rare GGLF. Additionally, there was focal microvascular
proliferation as well as focal pseudopalisading necrosis,
further evidence of its anaplastic nature. Immunohisto-
chemical studies revealed cytoplasmic and Golgi-like
synaptophysin positivity in both dysmorphic ganglion cells
and a subset of the oligodendroglioma cells. The dysmor-
phic ganglion cells were also variably immunoreactive for
neuroﬁlament protein and Neu-N, while the oligodendro-
glioma cells were negative. Subsets of tumor cells were
strongly GFAP positive, mostly showing morphologic fea-
tures of minigemistocytes and glioﬁbrillary oligoden-
drocytes. Endothelial cells stained appropriately for CD34,
although tumor cells were negative. The Ki-67 labeling
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oligodendroglial component. Dysmorphic ganglion cells
were negative. FISH studies were performed on the recur-
rent tumor and showed 1p and 19q codeletion. However,
there were too few dysmorphic ganglion cells to reliably
analyze the GGLF portion.
Case 5
This 55-year-old man was admitted for a several-month
history of personality change and more recently had been
becoming increasingly drowsy and was noted to be drag-
ging his left foot. A CT scan of the head revealed a large
cystic mass in the right frontal lobe with compression of
the frontal horn of the right lateral ventricle and right-to-
left shift. Decreased signal was seen extending throughout
the white matter of the frontal lobe across the genu of the
corpus callosum into the left frontal lobe. An MRI of the
head conﬁrmed the large complex mass with contrast
enhancement of the solid component, as well as a portion
of the rim of the cystic component. However, the
enhancing component did not extend into the corpus cal-
losum. The differential diagnosis was glioblastoma or
possibly a metastatic deposit. While in the hospital, his
condition deteriorated and he was given dexamethasone
with some improvement. A CT scan of the head revealed a
Fig. 6 The oligodendroglioma
and GGLF in case 5 are
displayed on the left and right
sides, respectively. The former
appeared low-grade (a), while
tight clusters of unmistakably
dysmorphic ganglion cells
characterized the latter (b). The
majority of oligodendroglioma
cells were negative for
synaptophysin (c) and Neu-N
(e), although both these stains
highlighted entrapped native
elements, consistent with an
inﬁltrative growth pattern.
Dysmorphic ganglion cells were
strongly synaptophysin positive
(d), but mostly Neu-N negative
(f). GFAP stains highlighted
mostly reactive appearing
astrocytes in the
oligodendroglioma regions (g)
and tumoral astrocytes in the
GGLF (h)
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123new large intratumoral hemorrhage. An emergent craniot-
omy was performed with drainage of the cyst and a subtotal
resection of the tumor, which appeared to extend into the
temporal lobe. The patient received adjuvant external beam
radiotherapy with a total dose of 59.4 Gy in 33 fractions.
MRI studies performed 6 months post-operatively revealed
a new focus of contrast enhancement suspicious for
recurrence, which decreased in size on the most recent
imaging 2 months later. However, the extent of the sur-
rounding non-enhancing T2/FLAIR signal abnormality had
increased. The latest plan was to see him again in
3 months, with the possibility of chemotherapy if imaging
revealed tumor progression.
The pathology specimen was very similar in appearance
to case 1, except that the oligodendroglial component
appeared low-grade (WHO grade II), with low mitotic
activity and no evidence of either microvascular prolifera-
tion or necrosis (Fig. 6a). Dysmorphic ganglion cells
(Fig. 6b) displayed strong cytoplasmic and membrane pat-
tern positivity for synaptophysin (Fig. 6d), but were nearly
uniformly negative for Neu-N (Fig. 6f). No EGBs were
seen. Weak cytoplasmic positivity for synaptophysin was
seen in occasional oligodendroglioma cells as well, but
mostly highlighted entrapped neuropil (Fig. 6c); Neu-N
stained only entrapped cortical neurons (Fig. 6e). Scattered
GFAP-positive cells were seen in both components,
althoughintheGGLFtheyappearedconsistentwithtumoral
astrocytes (Fig. 6h), while in the oligodendroglioma portion
most positive cells looked like reactive astrocytes (Fig. 6g).
Occasional glioﬁbrillary oligodendrocytes were also noted.
Tumor cells were CD34 negative, while intratumoral
endothelial cells were positive. The Ki-67 stain reached a
maximal labeling index of roughly 8% in the oligodendro-
glioma component, but stained only rare small perivascular
cells in the GGLF (similar to Fig. 3h). FISH studies showed
chromosome 1p deletion in both components (Fig. 7a, b),
while chromosome 19 studies showed a normal disomic
(2 copies) dosage in both regions (Fig. 7c, d), i.e., there was
no evidence of 19q deletion.
Case 6
This 63-year-old woman presented with a 2-week history
of progressive ataxia, falls, confusion, and word ﬁnding
difﬁculties. She also had headaches for a few days. After a
few falls and increasingly bizarre behavior, her husband
brought her to the hospital for medical attention. Head CT
and MRI were eventually included in the workup and they
showed a large, minimally enhancing left frontal lobe mass
with speckled calciﬁcations, an inﬁltrative pattern, and
extension across the corpus callosum to the right frontal
lobe (Fig. 8). There was moderate associated edema and
considerable mass effect with partial compression of the
left lateral ventricle. A large, but subtotal resection was
performed. The patient is currently undergoing combined
chemoradiotherapy, with temozolomide as the chemother-
apeutic agent. No additional follow-up is available given
that the patient was only recently diagnosed.
Fig. 7 FISH images from the
oligodendroglioma region and
GGLF of case 5 are illustrated
on the left and right sides,
respectively. Both components
showed evidence of
chromosome 1p deletion (a, b),
but retained chromosome 19
dosages (c, d)
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123The pathological ﬁndings in this case were striking for at
least two distinct morphological appearances, which were
sharply demarcated from one another focally (Fig. 9a), but
were intimately intermingled in most areas. The predomi-
nant cell type was that of an anaplastic oligodendroglioma
with classical cytological features (Fig. 9b), up to 6 mito-
ses per 10 high powered ﬁelds, and focal necrosis, but no
deﬁnite microvascular proliferation. Additionally, scattered
enlarged, bizarre and sometimes multinucleated astrocytes
were interspersed among the oligodendroglioma cells
(Fig. 9b); it was unclear whether these represented reac-
tive, dysplastic, or neoplastic elements. Moreover, there
were several small foci of neurocytic differentiation with
delicate neuropil formation and neurocytic rosettes
(Fig. 9d). The GGLF featured microcystic spaces (Fig. 9c)
and large dysmorphic neurons, including binucleate forms
(Fig. 9e; arrow). Even in these areas, however, there were
scattered smaller oligodendroglioma cells, including
minigemistocytes (Fig. 9e; arrowheads). No EGBs were
seen. Neuronal markers, such as synaptophysin, chro-
mogranin, neuroﬁlament protein, and Neu-N variably
stained the dysmorphic ganglion cells in GGLF, as well as
entrapped native elements within the oligodendroglioma
regions (Fig. 10). GFAP highlighted scattered astrocytic
elements in both foci, including the enlarged bizarre forms
(Fig. 10e, f). Intratumoral endothelial cells stained appro-
priately for CD34, but tumor cells were negative. The
Ki-67 labeling index was estimated at roughly 10% in the
oligodendroglioma component and \1% in the GGLF.
Codeletion of 1p and 19q was seen in both components
using FISH (Fig. 11). Most of the dysmorphic ganglion
cells appeared near-tetraploid with two test and four ref-
erence probe signals, while most of the oligodendroglioma
cells appeared near-diploid with one test and two reference
probe signals.
Case 7
This 42-year-old man presented with a 1-month history of
progressive headaches, nausea, and vomiting. MRI studies
revealed an 8.2 9 6.9 9 5 cm heterogeneously enhancing
mass in the right frontal lobe with marked mass effects,
including a 16-mm midline shift and compression of both
frontal horns of the lateral ventricles. There were several
cystic regions and one region with imaging characteristics
of intratumoral hemorrhage. The radiographic impression
was that of a high-grade diffuse glioma. A subtotal resec-
tion was recently performed and there are plans to treat the
patient further with combined radiation and temozolomide
therapy.
In the majority of slides from the resection specimen, the
tumor had features of an anaplastic oligoastrocytoma, WHO
grade III, wherein the oligodendroglial (classic and mini-
gemistocytic) and astrocytic (ﬁbrillary and gemistocytic)
elements were intermixed. Anaplastic features included up
to 9 mitoses per 10 high-powered ﬁelds and focal micro-
vascular proliferation. No necrosis was found. GGLF were
found in one slide, showing both demarcated and inter-
mixed borders with adjacent glial elements. Multinucleated
forms were common and the mitotic index was low in these
regions, but no EGBs were seen. Strong GFAP positivity
was seen in glial elements from both components. Dys-
morphic ganglion cells showed widespread membrane and
Golgi-like patterns of immunoreactivity for synaptophysin,
while the glial elements were mostly negative. Rare dys-
morphic ganglion cells displayed chromogranin positivity,
but they were negative for both neuroﬁlament protein and
Neu-N. Endothelial cells strongly expressed CD34, but all
tumor cells were negative. The Ki-67 labeling index was
estimated at 12% in the glioma component, while dys-
morphic ganglion cells were essentially negative. FISH
Fig. 8 Pre-operative MRI from
patient 6 showed a minimally
enhancing diffuse left frontal
lobe mass with extension across
the corpus callosum into the
right frontal lobe on axial post-
contrast T1-weighted (a) and
axial FLAIR (b) images
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123studies showed polysomies (gains) of both chromosomes
1 and 19, with no evidence of deletions.
Discussion
The cases presented in this series were novel and created
considerable diagnostic difﬁculties. In most, the diagnosis
of ganglioglioma with an oligodendroglial component was
originally favored, but the presence of anaplastic features
was cause for concern. As such, the possibility of ana-
plastic ganglioglioma was also considered. On further
analysis however, the presence of 1p and 19q codeletion in
the majority of our cases, along with the ﬁnding of iden-
tical genetic alterations in both components suggested
the opposite interpretation. In other words, this genetic
signature is highly associated with the diagnosis of oligo-
dendroglioma and is fairly speciﬁc to oligodendroglial
neoplasms in general [1, 18, 29]. In contrast, it has never
been reported in gangliogliomas [16, 26, 41]. Therefore,
Fig. 9 The histologic
examination of case 6 showed
focal demarcation between the
oligodendroglioma (a; left) and
ganglioglioma-like (a; right)
components, but also consisted
of intermingled elements. The
oligodendroglial cytology had
classic features (b, d), but also
included scattered large bizarre
astrocytes (b) and small foci of
neurocytic differentiation with
rosette formation (d). The
ganglioglioma-like foci had
microcystic growth pattern (c),
enlarged dysmorphic ganglion
cells including occasional
binucleate forms (e; arrow), as
well as scattered
oligodendroglial cells and
minigemistocytes (e;
arrowheads)
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123our interpretation was that these were essentially oligo-
dendrogliomas with ganglioglioma-like maturation. We
believe that this represents an unusual form of neuronal and
to a lesser degree, astrocytic differentiation, somewhat
analogous to prior studies showing foci of neurocytic dif-
ferentiation in oligodendrogliomas [20, 22, 28, 36]. This
potential link between these two forms of neuronal matu-
ration was further strengthened by the ﬁnding of both
Fig. 10 Immunohistochemical
results in case 6, with the
oligodendroglioma component
on the left and the
ganglioglioma component on
the right. Chromogranin
highlighted scattered small
entrapped cortical ganglion cells
in the oligodendroglial element
(a) and the majority of
dysmorphic ganglion cells in
GGLF (b). Similar results were
obtained with the Neu-N stain
(c, d), although dysmorphic
ganglion cells stained more
variably, including occasional
negativity in abnormal
appearing cells (d; binucleate
cell on the right). Most
oligodendroglioma cells were
negative for GFAP (e), except
for patchy staining in
minigemistocytes and
glioﬁbrillary oligodendrocytes
(not shown). However, the
scattered bizarre astrocytes were
strongly positive (e). A GFAP-
positive astrocytic element was
also seen in ganglioglioma-like
foci (f)
Fig. 11 FISHincase 6showeda
1p (a)a n d1 9 q( b) codeletion
patternsimilartothatencountered
in case #1 (see Fig. 4). In
ganglioglioma-like foci, the
majority of enlarged dysmorphic
ganglioncellsshowedatetraploid
p a t t e r n( 2t e s ta n d4r e f e r e n c e
probesignals;arrowheadinaand
arrows in b), while the adjacent
smaller oligodendroglioma cells
displayedmostlyadiploidpattern
(1 test and 2 reference probe
signals; arrows in a and
arrowhead in b). In these images,
the larger nuclei represent the
ganglion cells, whereas the
smaller nuclei represent
oligodendroglioma cells. The
delicate ﬁbrillary matrix in
between is neuropil
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123neurocytic and gangliocytic maturation in one of our
tumors (case 6). Otherwise, however, the potential mimicry
between this morphologic pattern and the entity of gan-
glioglioma was striking. Of note, there were at least a few
important differences. Whereas the great majority of gan-
gliogliomas display at least some EGBs, none were found
in the GGLF of our tumors. Additionally, roughly 70–80%
of gangliogliomas display variable numbers of intratumoral
and/or peritumoral CD34-positive cells, often with a
characteristic cytology that includes highly ramiﬁed cyto-
plasmic processes [4, 6, 10]. Positivity has even been
described in anaplastic gangliogliomas, although it is also
known to be lost in some cases during malignant pro-
gression [19]. In our cases, this marker was uniformly
negative, with intratumoral endothelial cells providing a
useful internal control. As such, this may be a particularly
useful immunostain in those rare cases where both diag-
nostic possibilities are being considered. Overall,
perivascular lymphocytic cufﬁng was also less prominent
in our cases than in gangliogliomas, although some
inﬂammation was occasionally found. However, similar to
gangliogliomas and in contrast to entrapped non-neoplastic
cortical neurons, the dysmorphic ganglion cells in our
tumors often displayed more variable Neu-N expression or
were entirely negative. Therefore, Neu-N may be a useful
immunostain for excluding the native ganglion cells that
occasionally show mildly dysmorphic features in the midst
of an inﬁltrating glioma. It is possible that MAP2 staining
patterns could further aid in this distinction [5, 7, 32, 34],
although this marker was not generally available in the
primary author’s institution and was also not utilized by
any of the referring pathologists. Therefore, future studies
are needed to assess its potential utility for this differential
diagnosis.
In addition to these histologic and genetic features dis-
tinguishing gangliogliomas from oligodendrogliomas with
ganglioglioma-like maturation, there were signiﬁcant
clinical and neuroimaging clues in our cases. These
patients were generally older than those with gangliogli-
oma; they lacked the typical long histories of chronic
seizure disorder; and neuroimaging studies showed char-
acteristic ﬁndings of diffuse gliomas in general, i.e.,
inﬁltrative cerebral hemispheric neoplasms with signiﬁcant
mass effects and common involvement of the corpus
callosum. In contrast, gangliogliomas are classically
demarcated, often cystic, with a mural contrast enhancing
nodule, and most commonly involve the mesial temporal
lobe [35]. Unlike diffuse gliomas, complete surgical exci-
sion is feasible in most cases and is often curative without
any need for adjuvant therapy. Although there is insufﬁ-
cient data to determine for certain whether the presence of
ganglioglioma-like maturation has any prognostic impact
in oligodendrogliomas, our follow-up data to date would
suggest that the clinical behavior is analogous to otherwise
classical examples without neuronal features and of similar
grade and molecular genetic background. This includes a
long-term risk of recurrences and eventual death from
progressive disease. For instance, the median overall sur-
vival times for patients with classical anaplastic
oligodendrogliomas at Washington University were
recently reported as 11.3 and 5.7 years, corresponding to
tumors with and without 1p/19q codeletion, respectively
[21]. Progression free survival times are similarly longer in
patients with codeleted anaplastic oligodendrogliomas,
although they vary considerably from one patient to
another [8, 37]. Therefore, although longer follow-up is
clearly needed for more deﬁnitive comparisons, the pres-
ence of one death at 7.5 years and two recurrences at
2–3 years seems par for the course.
Of interest, there have been rare reports of tumors
interpreted as ‘‘ganglioglioma with an anaplastic oligoden-
droglial component’’ or ‘‘oligodendroglial ganglioglioma
with anaplastic features’’ [2, 15, 17]. Probably the ﬁrst was
a 45-year-old woman with a heterogeneously enhancing
left frontal lobe mass reported in 1990 by Allegranza and
colleagues [2]. Unfortunately, this paper was scantly
illustrated and documented by today’s standards. None-
theless, based on the descriptions in the text, it appears very
similar to those of the current study. As with our cases, this
tumor was subtotally resected due to an ill-deﬁned or
inﬁltrative border. Based on the pathological ﬁndings, the
interface between the two components was sharp in some
areas and intermingled in others. Dysmorphic and binu-
cleate ganglion cells displayed Nissl substance and were
neuroﬁlament positive, whereas the oligodendroglial
component was Leu-7 positive and GFAP negative. No
additional support for the interpretation of ganglioglioma
with an anaplastic oligodendroglioma component was
given, although it appeared to be partially based on a
consultation diagnosis rendered by Dr. Lucien Rubenstein.
No long-term clinical follow-up was provided. Another
case was reported as part of a larger series of ganglio-
gliomas in adults [15]. Unfortunately, this case was not
elucidated in much detail. It represented a 26-year-old man
with a frontal lobe mass that was treated with gross total
resection, radiation, and chemotherapy. Despite therapy,
this patient died 47 months after surgery. A third case was
reported in a 17-year-old girl with a massive, partially
enhancing, and hemorrhagic thalamic mass that extended
into the brainstem [17]. This case also had some overlap-
ping features with ours, although the authors reported
ﬁnding rare EGBs in their case and the patient was younger
than those described in the current series. As such, it is
difﬁcult to determine whether this case was the same
phenomenon described in our paper or could poten-
tially represent a true ganglioglioma with an anaplastic
250 Acta Neuropathol (2010) 120:237–252
123oligodendroglial component. None of the previously
reported cases included genetic studies.
In summary, we report a new form of neuronal and to a
lesser extent, astrocytic differentiation in oligodendroglial
neoplasms. We refer to this pattern as ‘‘ganglioglioma-like
maturation’’ given the combined morphologic and immuno-
histochemical evidence of ganglion cell differentiation and
the loss of proliferative activity in comparison to adjacent
oligodendroglial components. However, these GGLF differ
from true gangliogliomas in their lack of (1) ganglioglioma-
likedemographic,clinical,andradiologicfeatures,(2)EGBs,
and(3)CD34-positivetumorcells.Additionally,thesetumors
often harbor the 1p/19q codeletion pattern typical ofclassical
oligodendroglioma,ageneticsignaturewhichwasfoundeven
in dysmorphic ganglion cells. This genetic ﬁnding supports a
common lineage for the two otherwise strikingly dissimilar
histologic patterns. Awareness of this morphologic variant
could prevent the misdiagnosis of ‘‘ganglioglioma with an
oligodendrogliomacomponent’’,avertingthepotentialriskof
under-treating these patients.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects
of 1p/19q loss and the diagnosis of oligodendroglioma. Arch
Pathol Lab Med 131:242–251
2. Allegranza A, Pileri S, Frank G, Ferracini R (1990) Cerebral
ganglioglioma with anaplastic oligodendroglial component. His-
topathology 17:439–441
3. Bailey P, Bucy PC (1929) Oligodendrogliomas of the brain. J
Pathol Bacteriol 32:735–751
4. Blumcke I, Giencke K, Wardelmann E, Beyenburg S, Kral T,
Sarioglu N, Pietsch T, Wolf HK, Schramm J, Elger CE, Wiestler
OD (1999) The CD34 epitope is expressed in neoplastic and
malformative lesions associated with chronic, focal epilepsies.
Acta Neuropathol (Berl) 97:481–490
5. Blumcke I, Becker AJ, Normann S, Hans V, Riederer BM,
Krajewski S, Wiestler OD, Reifenberger G (2001) Distinct
expression pattern of microtubule-associated protein-2 in human
oligodendrogliomas and glial precursor cells. J Neuropathol Exp
Neurol 60:984–993
6. Blumcke I, Wiestler OD (2002) Gangliogliomas: an intriguing
tumor entity associated with focal epilepsies. J Neuropathol Exp
Neurol 61:575–584
7. Blumcke I, Muller S, Buslei R, Riederer BM, Wiestler OD (2004)
Microtubule-associated protein-2 immunoreactivity: a useful tool
in the differential diagnosis of low-grade neuroepithelial tumors.
Acta Neuropathol (Berl) 108:89–96
8. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B,
Brachman D, Buckner J, Fink K, Souhami L, Laperierre N,
Mehta M, Curran W (2006) Phase III trial of chemotherapy plus
radiotherapy compared with radiotherapy alone for pure and
mixed anaplastic oligodendroglioma: Intergroup Radiation
Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714
9. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM,
Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y,
Ramsay DA, Louis DN (1998) Speciﬁc genetic predictors of
chemotherapeutic response and survival in patients with ana-
plastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479
10. Deb P, Sharma MC, Tripathi M, Sarat Chandra P, Gupta A,
Sarkar C (2006) Expression of CD34 as a novel marker for
glioneuronal lesions associated with chronic intractable epilepsy.
Neuropathol Appl Neurobiol 32:461–468
11. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari
K, Lair S, Marie Y, Paris S, Vidaud M, Hoang-Xuan K, Delattre
O, Delattre JY, Sanson M (2008) Anaplastic oligodendrogliomas
with 1p19q codeletion have a proneural gene expression proﬁle.
Mol Cancer 7:41
12. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W,
Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A (2004)
Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in
recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314–
322
13. Ferrer-Luna R, Mata M, Nunez L, Calvar J, Dasi F, Arias E,
Piquer J, Cerda-Nicolas M, Taratuto AL, Sevlever G, Celda B,
Martinetto H (2009) Loss of heterozygosity at 1p–19q induces a
global change in oligodendroglial tumor gene expression. J
Neurooncol 95:343–354
14. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB,
Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligoden-
droglial tumors: reﬁning the correlation among histopathology,
1p 19q deletion and clinical outcome in Intergroup Radiation
Therapy Oncology Group Trial 9402. Brain Pathol 18:360–369
15. Hakim R, Loefﬂer JS, Anthony DC, Black PM (1997) Ganglio-
gliomas in adults. Cancer 79:127–131
16. HoischenA,EhrlerM,FassunkeJ,SimonM,BaudisM,Landwehr
C, Radlwimmer B, Lichter P, Schramm J, Becker AJ, Weber RG
(2008) Comprehensive characterization of genomic aberrations in
gangliogliomas by CGH, array-based CGH and interphase FISH.
Brain Pathol 18:326–337
17. Johnson MD, Jennings MT, Toms ST (2001) Oligodendroglial
ganglioglioma with anaplastic features arising from the thalamus.
Pediatr Neurosurg 34:301–305
18. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA,
Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling
P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ,
Allgeier A, Lacombe D, van den Bent MJ (2009) Molecular
analysis of anaplastic oligodendroglial tumors in a prospective
randomized study: a report from EORTC study 26951. Neuro
Oncol 11:737–746
19. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ,
Simon M (2008) Tumor recurrence and malignant progression of
gangliogliomas. Cancer 113:3355–3363
20. Makuria AT, Henderson FC,Rushing EJ, Hartmann DP, AzumiN,
Ozdemirli M (2007) Oligodendroglioma with neurocytic differ-
entiation versus atypical extraventricular neurocytoma: a case
report of unusual pathologic ﬁndings of a spinal cord tumor. J
Neurooncol 82:199–205
21. Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Sig-
niﬁcance of necrosis in grading of oligodendroglial neoplasms: a
clinicopathologic and genetic study of newly diagnosed high-
grade gliomas. J Clin Oncol 24:5419–5426
22. Mrak RE, Yasargil MG, Mohapatra G, Earel J Jr, Louis DN
(2004) Atypical extraventricular neurocytoma with oligodendro-
glioma-like spread and an unusual pattern of chromosome 1p and
19q loss. Hum Pathol 35:1156–1159
23. Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T,
Nishikawa R, Asai A, Kirino T, Aburatani H (2004) Selective
expression of a subset of neuronal genes in oligodendroglioma
with chromosome 1p loss. Brain Pathol 14:34–42
Acta Neuropathol (2010) 120:237–252 251
12324. Mut M, Guler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE
(2005) Challenging diagnosis: oligodendroglioma versus extra-
ventricular neurocytoma. Clin Neuropathol 24:225–229
25. Ng HK, Ko H, Tse C (1994) Immunohistochemical and ultra-
structural studies of oligodendrogliomas revealed features of
neuronal differentiation. Int J Surg Pathol 2:47–56
26. Pandita A, Balasubramaniam A, Perrin R, Shannon P, Guha A
(2007) Malignant and benign ganglioglioma: a pathological and
molecular study. Neuro Oncol 9:124–134
27. Patt S, Labrakakis C, Bernstein M, Weydt P, Cervos-Navarro J,
Nisch G, Kettenmann H (1996) Neuron-like physiological prop-
erties of cells from human oligodendroglial tumors. Neuroscience
71:601–611
28. Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros
JM (2002) Oligodendrogliomas with neurocytic differentiation. A
report of 4 cases with diagnostic and histogenetic implications. J
Neuropathol Exp Neurol 61:947–955
29. Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW (2003)
Ancillary FISH analysis for 1p and 19q status: preliminary
observations in 287 gliomas and oligodendroglioma mimics.
Front Biosci 8:a1–a9
30. Reifenberger G, Kros JM, Louis DN, Collins VP (2007) Oligo-
dendroglioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK (eds) WHO classiﬁcation of tumours of the central nervous
system. IARC, Lyon, pp 54–59
31. Reifenberger J, Reifenberger G, Liu L et al (1994) Molecular
genetic analysis of oligodendroglial tumors shows preferential
allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190
32. Shaﬁt-Zagardo B, Davies P, Rockwood J, Kress Y, Lee SC
(2000) Novel microtubule-associated protein-2 isoform is
expressed early in human oligodendrocyte maturation. Glia
29:233–245
33. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM,
Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB
(2000) Alterations of chromosome arms 1p and 19q as predictors
of survival in oligodendrogliomas, astrocytomas, and mixed oli-
goastrocytomas. J Clin Oncol 18:636–645
34. Suzuki SO, Kitai R, Llena J, Lee SC, Goldman JE, Shaﬁt-Za-
gardo B (2002) MAP-2e, a novel MAP-2 isoform, is expressed in
gliomas and delineates tumor architecture and patterns of inﬁl-
tration. J Neuropathol Exp Neurol 61:403–412
35. Urbach H (2008) MRI of long-term epilepsy-associated tumors.
Semin Ultrasound CT MR 29:40–46
36. Vajtai I, Arnold M, Vassella E (2005) Oligodendroglioma with
neurocytic differentiation and characteristic loss of heterozygos-
ity on chromosomes 1p and 19q. Acta Neuropathol (Berl)
110:520–522
37. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M,
Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W,
Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC,
Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant
procarbazine, lomustine, and vincristine improves progression-
free survival but not overall survival in newly diagnosed ana-
plastic oligodendrogliomas and oligoastrocytomas: a randomized
European Organisation for Research and Treatment of Cancer
phase III trial. J Clin Oncol 24:2715–2722
38. Vyberg M, Ulhoi BP, Teglbjaerg PS (2007) Neuronal features of
oligodendrogliomas—an ultrastructural and immunohistochemi-
cal study. Histopathology 50:887–896
39. Wharton SB, Chan KK, Hamilton FA, Anderson JR (1998)
Expression of neuronal markers in oligodendrogliomas: an
immunohistochemical study. Neuropathol Appl Neurobiol
24:302–308
40. Wolf HK, Buslei R, Blu ¨mcke I et al (1997) Neural antigens in
oligodendrogliomas anddysembryoplastic neuroepithelial tumors.
Acta Neuropathol (Berl) 94:436–443
41. Yin XL, Hui AB, Pang JC, Poon WS, Ng HK (2002) Genome-
wide survey for chromosomal imbalances in ganglioglioma using
comparative genomic hybridization. Cancer Genet Cytogenet
134:71–76
252 Acta Neuropathol (2010) 120:237–252
123